A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Bionoxx Inc.
KaliVir Immunotherapeutics
Bionoxx Inc.
Genentech, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
M.D. Anderson Cancer Center
Genentech, Inc.
Inimmune Corporation
Genentech, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MediLink Therapeutics (Suzhou) Co., Ltd.
Amgen
Affimed GmbH
Genentech, Inc.
Adlai Nortye Biopharma Co., Ltd.
EMD Serono
Xilio Development, Inc.
Hoffmann-La Roche
Gruppo Oncologico Italiano di Ricerca Clinica
Chugai Pharmaceutical
Hoffmann-La Roche
Omico
Immunocore Ltd
Uppsala University Hospital
Swiss Cancer Institute
University Hospital, Antwerp
University Medical Center Groningen
Pieris Pharmaceuticals, Inc.
Hoffmann-La Roche
Rain Oncology Inc
Dracen Pharmaceuticals, Inc.
Beijing Friendship Hospital
University of Leicester
Jules Bordet Institute
Hoffmann-La Roche
Health Pharma Professional Research
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Genentech, Inc.